|Articles|January 15, 2003
- BioPharm International-01-01-2003
- Volume 16
- Issue 1
Rethinking the Economics of Chromatography: New Technologies and Hidden Costs
Author(s)Tim N. Warner, Sam Nuchumson
by Tim N. Warner and Sam Nuchumson, Pall Life Sciences If the hidden expenses associated with laboratory purchases ? labor, cleaning, buffers, validation, time delays ? are identified, reduced processing costs, higher throughput, and accelerated time-to-market are possible. This comparison between resin and membrane chromatography helps shed light on some hidden costs.
Advertisement
Articles in this issue
about 23 years ago
Biotech World: Canada's Supreme Court says "No" to Harvard Mouseabout 23 years ago
Guest Editorial: At the Governance Crossroadabout 23 years ago
Reducing Costs by Facility Designabout 23 years ago
Guidelines for Optimization and Scale-Up in Preparative Chromatographyabout 23 years ago
Survival Strategies: Board Compensation Changing with the TimesNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
How CDMO Alliances Can Provide End-to-End Service that Reduces Drug Development Time and Costs
2
First-in-Human Study Validates Safety of Next-Generation mRNA–LNP Platform
3
Industry Outlook 2026: Key Forces Transforming Drug Pipelines (Part 2)
4
Eli Lilly Announces New $3.5 Billion Manufacturing Facility in Pennsylvania
5
